用于诊断阿尔茨海默病的功能纳米材料:最近的进展和未来的前景
Saqer Al Abdullah1, Lubna Najm2, Liane Ladouceur3
1Department of Nanoengineering, Joint School of Nanoscience and Nanoengineering, North Carolina A&T State University, 2907 East Gate City Boulevard, Greensboro, NC 27401, USA.
概括
早期发现阿尔茨海默氏病 (AD) 是至关重要的. 新型纳米生物材料生物传感器提供了有前途的方法,在患者样本中识别AD生物标志物,在症状出现之前,帮助早期诊断.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 神经科学是一个神经科学.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特点是神经元功能障碍和认知能力下降.
- 目前的AD诊断通常是在临床症状出现后进行的,这限制了早期干预.
- 早期的病理特征包括粉样β (Aβ) 斑块和神经纤维状结 (NFT).
研究的目的:
- 审查新兴的纳米生物材料方法,用于开发生物传感器来检测阿尔茨海默病的生物标志物.
- 讨论AD诊断的各种生物传感模式的进展,挑战和潜力.
- 评估这些新型生物传感器的临床整合标准.
主要方法:
- 针对AD生物标志物的纳米生物材料生物传感器的综合文献综述.
- 分析电化学,光学和色度生物传感技术.
- 专注于纳米粒子 (金属,磁,量子点) 和基于纳米结构的生物材料.
主要成果:
- 纳米生物材料生物传感器显示出检测关键AD生物标志物如Aβ和tau蛋白的显著潜力.
- 使用纳米粒子和纳米结构的各种生物传感平台 (电化学,光学,色度) 正在发展.
- 这些生物传感器可以分析患者样本中的生物标志物,例如CSF和血液.
结论:
- 新兴的纳米生物材料生物传感器对早期阿尔茨海默病诊断有很大的前景.
- 为了成功的临床翻译,需要进一步的开发和验证.
- 这些技术可以显著提高早期AD检测和管理.
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170


